Trial · NCT01163253
Results by group906
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 906
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Tofacitinib 10 mg | AEs | 1876 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Tofacitinib 5 mg or 10 mg | AEs | 490 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Tofacitinib 10 mg | SAEs | 304 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Tofacitinib 5 mg or 10 mg | SAEs | 88 | participants | |
| Number of Adverse Events (AEs) by Severity | Tofacitinib 10 mg | Mild | 5354 | adverse events | |
| Number of Adverse Events (AEs) by Severity | Tofacitinib 5 mg or 10 mg | Mild | 1749 | adverse events | |
| Number of Adverse Events (AEs) by Severity | Tofacitinib 10 mg | Moderate | 3268 | adverse events | |
| Number of Adverse Events (AEs) by Severity | Tofacitinib 5 mg or 10 mg | Moderate | 766 | adverse events | |
| Number of Adverse Events (AEs) by Severity | Tofacitinib 10 mg | Severe | 410 | adverse events | |
| Number of Adverse Events (AEs) by Severity | Tofacitinib 5 mg or 10 mg | Severe | 136 | adverse events | |
| Number of Participants With Laboratory Abnormalities | Tofacitinib 10 mg | 2203 | participants | ||
| Number of Participants With Laboratory Abnormalities | Tofacitinib 5 mg or 10 mg | 565 | participants | ||
| Change From Baseline in Hemoglobin Level at Month 1 | Tofacitinib 10 mg | Baseline (n =2277, 586) | 14.64 | Standard Deviation 1.27 | gram per deciliter (g/dL) |
| Change From Baseline in Hemoglobin Level at Month 1 | Tofacitinib 5 mg or 10 mg | Baseline (n =2277, 586) | 14.64 | Standard Deviation 1.24 | gram per deciliter (g/dL) |
| Change From Baseline in Hemoglobin Level at Month 1 | Tofacitinib 10 mg | Change at Month 1 (n =2201, 563) | -0.24 | Standard Deviation 0.83 | gram per deciliter (g/dL) |
| Change From Baseline in Hemoglobin Level at Month 1 | Tofacitinib 5 mg or 10 mg | Change at Month 1 (n =2201, 563) | -0.32 | Standard Deviation 0.86 | gram per deciliter (g/dL) |
| Change From Baseline in Hemoglobin Level at Month 3 | Tofacitinib 10 mg | -0.27 | Standard Deviation 0.85 | g/dL | |
| Change From Baseline in Hemoglobin Level at Month 3 | Tofacitinib 5 mg or 10 mg | -0.39 | Standard Deviation 0.83 | g/dL | |
| Change From Baseline in Hemoglobin Level at Month 6 | Tofacitinib 10 mg | -0.27 | Standard Deviation 0.88 | g/dL | |
| Change From Baseline in Hemoglobin Level at Month 6 | Tofacitinib 5 mg or 10 mg | -0.30 | Standard Deviation 0.87 | g/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01163253/results